Finance

Beta
Lists
4577:TYO
Daito Pharmaceutical Co Ltd
Â¥1,138.00
-0.18%
(-2.00) 1D
Jun 3, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4577...
Open
Â¥1,140
High
Â¥1,141
Low
Â¥1,122
Mkt. cap
32.84B
Avg. vol.
84.27K
Volume
117.40K
Dividend
3.30%
Quarterly dividend
Â¥9
Ex-dividend date
May 28, 2026
P/E ratio
11.42
52-wk high
Â¥1,521
52-wk low
Â¥973
EPS
Â¥100
Shares outstanding
12.51M
No. of employees
1K
Open
Â¥1,140
High
Â¥1,141
Low
Â¥1,122
Mkt. cap
32.84B
Avg. vol.
84.27K
Volume
117.40K
Dividend
3.30%
Quarterly dividend
Â¥9
Ex-dividend date
May 28, 2026
P/E ratio
11.42
52-wk high
Â¥1,521
52-wk low
Â¥973
EPS
Â¥100
Shares outstanding
12.51M
No. of employees
1K
News stories
From sources across the web
About Daito Pharmaceutical Co Ltd
CEO-
Employees1.07K
FoundedJun 30, 1942
Headquarters-
SectorPharmaceutical industry
Websitedaitonet.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
May 2025
Aug 2025
Nov 2025
Feb 2026
Revenue
14.03B
13.01B
12.13B
11.59B
Cost of goods sold
11.77B
10.45B
9.92B
9.24B
Cost of revenue
11.77B
10.45B
9.92B
9.24B
Research and development expenses
2.52B
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-1.17B
1.56B
1.58B
1.23B
Operating expense
1.51B
1.56B
1.58B
1.23B
Total operating expenses
13.28B
12.01B
11.50B
10.46B
Operating income
752.00M
1.00B
627.00M
1.13B
Other non operating income
12.00M
-5.00M
102.00M
-1.00M
EBT including unusual items
548.00M
1.05B
782.00M
1.44B
EBT excluding unusual items
674.00M
975.00M
789.00M
1.21B
Income tax expense
-127.00M
376.00M
237.00M
387.00M
Effective tax rate
-23.18%
35.74%
30.31%
26.97%
Other operating expenses
-
-
-
-
Net income
691.00M
696.00M
537.00M
1.03B
Net profit margin
4.92%
5.35%
4.43%
8.92%
Earnings per share
-
-
-
-
Interest and investment income
2.00M
32.00M
7.00M
29.00M
Interest expense
-38.00M
-30.00M
-33.00M
-33.00M
Net interest expenses
-36.00M
2.00M
-26.00M
-4.00M
Depreciation and amortization charges
164.00M
-
-
-
EBITDA
1.84B
2.08B
1.69B
2.21B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer